Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract


Authors: Goodman, O. B.; Chi, K. N.; Molina, A.; Logothetis, C.; Jones, R. J.; Staffurth, J.; North, S. A.; Vogelzang, N. J.; Saad, F.; Mainwaring, P. N.; Harland, S. J.; Li, J.; Kheoh, T. S.; Haqq, C. M.; Scher, H. I.; Fizazi, K.
Abstract Title: Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)
Meeting Title: 48th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 30
Issue: 15 Suppl.
Meeting Dates: 2012 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2012-05-20
Language: English
ACCESSION: WOS:000318009802774
PROVIDER: wos
DOI: 10.1200/jco.2012.30.15_suppl.4558
Notes: Meeting Abstract: 4558 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1133 Scher